Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Single-agent daratumumab activity in refractory multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses a phase 2 study evaluating single-agent daratumumab activity in patients with heavily pretreated refractory multiple myeloma.